| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-543
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-552
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16722
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16761 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-245
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04 |
| filingDate |
1997-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_74ecd433cbeeea53144edeb14aadcd0d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_413b5edd5cc0dc6cf8c746e24cc6a44b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67dbad7a91ea267d5b4eb11dcf420b43 |
| publicationDate |
2000-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
HU-0002374-A2 |
| titleOfInvention |
Recombinant type 1 horse herpesvirus (EHV-1) containing a dysfunctional 71 gene region and its use as a vaccine |
| abstract |
The present invention provides a vaccine composition comprising a live, recombinant, modified EHV-1 virus carrying a single dysfunctional 71 gene region within the U.S. region of the viral genome and a pharmaceutically acceptable carrier. Preferably, the vaccine of the invention comprises a live recombinant attenuated immunogenic EHV-171 gene deletion mutant virus. The invention further relates to such recombinant viruses and their uses. SHE |
| priorityDate |
1996-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |